Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a g 1 34.5-deficient herpes simplex virus type 1 (HSV-1) R849 for human oral squamous cell carcinoma (SCC) cells. Hexamethylene bisacetamide increased the viral yield, especially at a low input multiplicity of infection (MOI), and the transcription of immediate early genes of HSV-1. Hexamethylene bisacetamide treatment promoted the cytopathic effect of R849 and increased the proportion of dead cells. Hexamethylene bisacetamide produced more apoptotic cells in R849-infected cells as compared with parental HSV-1(F)-infected cells. The growth of oral SCC xenografts in nude mice was markedly suppressed by treatment with R849 in combination with HMBA, and the survival of the co-treated animals was significantly prolonged as compared with that of animals treated with R849 only. Herpes simplex virus type 1 mRNA was expressed in tumors and trigeminal neurons, but not in brain, lung, liver, and kidney. These results indicate that HMBA enhances the antitumor activity of R849 through the expression of immediate early genes without increasing its toxicity. Hexamethylene bisacetamide can be used as an enhancing agent for oncolytic therapy with HSV-1 mutants.
Introduction
One-half of patients with squamous cell carcinoma (SCC) of the head and neck present with advanced stage disease, and only approximately one-third of these patients survive 5 years with presently available therapies. 1 Oral SCC is a common cancer in the head and neck region. The majority of patients with oral SCC fail locally or regionally, with only a small fraction failing distantly. After recurrence, tumors are usually resistant to chemotherapy and radiotherapy, and a wide resection of the surrounding tissue is frequently needed, leading to a severe impairment of oro-facial structures and functions. 2, 3 Patients with advanced stage disease await the development of novel therapies.
Usage of replication-competent herpes simplex virus type 1 (HSV-1) mutants is a novel approach to cancer therapy, because the replication of viruses within cancer cells can result in their destruction. 4 Since the g 1 34.5 gene is responsible for the neurovirulence of HSV-1, 5,6 g 1 34.5 gene-deficient mutants are considered to be useful vectors for oncolytic therapy. So far, a number of malignant tumors including breast cancer, 7 prostate cancer, 8 lung cancer, 9 ovarian cancer, 10 malignant melanoma, 11 malignant glioma, 12 pancreatic cancer, 13 and head and neck cancer, 14, 15 have been tested for sensitivity to oncolytic therapy using g 1 34.5 gene-deficient mutants. Despite encouraging preclinical studies, results from clinical trials suggest that current oncolytic viruses, although safe, exert only limited antitumor activity on their own. [16] [17] [18] This is in part due to reduction in the replication potential of the virus within targeted tumors, because of elimination of the g 1 34.5 gene. Thus, it is necessary to increase viral oncolytic capability, using chemotherapeutic agents, cytokines and radiotherapy, or by constructing novel vectors. 9, [19] [20] [21] Indeed, a combination of chemotherapeutic drugs such as cisplatin and mitomycin C with HSV vectors was found to be effective for the treatment of head and neck cancer and lung cancer. 20, 22 The expression of the gibbon ape leukemia virus envelope fusogenic membrane glycoprotein by an oncolytic HSV-1 also potentiated the viral antitumor effect on human hepatocellular carcinoma, glioblastoma, and prostate cancer cells. 22 Earlier studies indicated that hexametylene bisacetamide (HMBA) caused murine erythroleukemia cells to adopt a less transformed phenotype, 23 and also enhanced the reactivation of HSV-1 from latency after the explanting of ganglia of infected mice. 24 Herpes simplex virus type 1 in1814 encoding an altered form of the virion transinducing factor VP16 is unable to transactivate immediate early transcription and initiates productive replication inefficiently in cultured cells. 25 This defect can be overcome by the inclusion of HMBA in the culture medium. Our previous results also indicated that HMBA enhanced the replication of wild-type HSV-1 in HEp-2 epidermal carcinoma cells and IMR-32 neuroblastoma cells. 26 A g 1 34.5 gene-deficient HSV-1 R3616 has 1000 bp deleted from the g 1 34.5 gene of wild-type HSV-1(F). The 1-kb pair deletion in R3616 was replaced with a lacZ gene inserted such that it was under the control of the g 1 34.5 promoter in the recombinant virus R849. 27 In the present study, we examined the possibility that HMBA could enhance the replication of the g 1 34.5 gene-deficient HSV-1 R849 and potentiate its oncolytic capability in oral SCC cells.
Materials and methods

Cells and virus
Human oral SCC cell lines Ca9-22 and SAS were obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan). FI was derived from a gingival cancer. 28 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin, and grown in an incubator at 371C in a humidified atmosphere with 5% CO 2 . FI cells were maintained in DMEM containing 5% FBS. Neonatal normal human epidermal keratinocyte (NHEK) was obtained from the Japanese Collection of Takara Biotechnology (Tokyo, Japan) and cultured in KBM-2 (Takara) supplemented with recombinant human epidermal growth factor, insulin, hydrocortisone, transferrin, epinephrine, gentamycin and amphotericin B. Herpes simplex virus type-1 strain F and HSV-1 mutant R849 (kindly provided by B Roizman) were grown in semiconfluent Vero cell monolayers. The infectivity of HSV-1 was determined by plaque formation on Vero cell monolayers covered with 0.3% methylcellulose. For purification of R849, infected cells were subjected to three cycles of freezing and thawing and then centrifuged at 3000 g for 15 min at 41C. The supernatant was centrifuged at 9000 g for 4 h at 41C, and the virus pellet was suspended in phosphate-buffered saline (PBS).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay Cells grown in 96-well culture dishes were infected with HSV-1 at multiplicity of infection (MOI) values ranging from 0.01 to 1, while controls were mock-infected. After incubation for various intervals, 10 ml of a 5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution was added to each well with 100 ml of medium. Cells were allowed to incubate for 4 h at 371C, and then 100 ml of 0.04 N HCl in isopropanol was added. They were mixed thoroughly to dissolve the dark blue crystal. After standing overnight at room temperature, the plates were read on a Benchmark Plus microplate spectrophotometer (Bio-Rad Laboratories, Hercules, CA) with a reference wavelength of 630 nm and a test wave length of 570 nm. Background absorbance at 690 nm was subtracted from 570 nm reading. Changes from room air controls were calculated. Data were the means7s.d. of six determinations.
Trypan blue staining and Hoechst staining Cell viability was determined by trypan blue dye exclusion analysis. Cells were dissociated in the ethylene diaminetetraacetic acid (EDTA)-trypsin solution, mixed with an equal volume of PBS without Ca 2 þ and Mg 2 þ containing 0.24% trypan blue, and observed with a microscope. Both stained and unstained cells were enumerated.
To identify apoptotic cells with DNA fragmentation, Hoechst staining was performed. Dissociated cells were fixed in PBS containing 1% glutaraldehyde (TAAB, Berkshire, UK) for 2 h. After washing in PBS, cells were stained with 200 mM Hoechst 33342, mounted on slides and observed with a fluorescent microscope.
Flow cytometric analysis
Cells were fixed in cold 80% ethanol for 1 h at 41C. The fixed cells were collected by centrifugation, and the pellet was resuspended in propiodium iodide (PI) staining reagent composed of 0.1% Triton X-100, 0.1 mM EDTA, 0.05 mg/ml RNase A (50 U/mg), and 50 mg/ml PI and then stored in the dark at room temperature until analyzed. Cell cycle analysis was performed with a fluorescenceactivated cell sorter (FACSort; Becton Dickinson, Mountain View, CA) and interpreted with Cell Quest (Becton Dickinson).
Reverse transcription-polymerase chain reaction and polymerase chain reaction analyses Total RNA was extracted from cells and mouse tissues using ISOGEN (Nippon gene, Tokyo, Japan), according to the manufacturer's instructions. Reverse transcriptionpolymerase chain reaction (RT-PCR) was performed using a Takara RNA PCR kit (Takara, Tokyo, Japan). One microgram of RNA was reverse-transcribed using avian myeloblastosis virus (AMV) reverse transcriptase, and cDNAs encoding the HSV-1 genes ICP0, ICP4, ICP27, thymidine kinase (TK), VP16, and b-actin gene sequences were amplified by PCR using specific primers. 29 To confirm the integrity of each RNA sample, PCR analysis of the b-actin gene was performed. The PCR amplification of cDNAs except for the ICP4 gene was carried out in volumes of 50 ml for 25 cycles at a denaturing temperature of 941C for 1 min, an annealing temperature of 551C for 2 min, and an extension temperature of 721C for 3 min using a GeneAmp PCR system 9700 (Applied Biosystems, CA). In the case of ICP4, annealing was performed at 601C for 2 min. Polymerase chain reaction products were subsequently size-fractionated on 1.5% agarose gels, stained with ethidium bromide and photographed under transmitted ultraviolet light.
DNA extracted from tumors and mouse tissues were used as templates for PCR. The sequences of the primers used were as follows: ICP6 forward, 5
0 -GACAGCCA-TATCCTGAGC-3 0 ; ICP6 reverse, 5 0 -ACTCACAGATC GTTGACGACCG-3 0 ; lac Z forward, 5 0 -GCGTTACCC AACTTAATCG-3 0 ; and lac Z reverse, 5 0 -TGTGAGCGA GTAACAACC-3 0 . 30 The PCR amplification was performed for 35 cycles at a denaturing temperature of 941C for 40 s, an annealing temperature of 601C for 30 s, and an extension temperature of 721C for 90 s.
Animal experiments
Experiments using FI xenografts in nude mice were performed with the approval of the Institute of Laboratory Animals, Osaka University Graduate School of Dentistry. Athymic 5-week-old BALB/c (nu/nu) female mice were obtained from Clea Japan (Tokyo, Japan). Mice were subcutaneously injected with 1 Â 10 6 FI cells into the buccal region. Once the subcutaneous tumor reached approximately 5 mm in diameter, 36 animals were divided into six groups of six animals each. On day 0, animals in groups 2 and 3 were given an intratumoral (i.t.) injection of 100 ml of 10 mM HMBA and an intraperitoneal (i.p.) injection of 500 mg/kg HMBA, respectively. On day 1, animals in groups 1, 2 and 3 were administered a single i.t. injection of 1 Â 10 7 plaque-forming units (PFU) of R849 suspended in 100 ml of PBS. From day 2 to 6, group 2 and 3 animals received i.t. injections and i.p. injections of HMBA, respectively, once a day. Group 4 and 5 animals were not given R849, but treated with i.t. injections of HMBA and i.p. injections of HMBA, respectively. Group 6 animals received PBS instead of R849 and were used as a control. The experiment was started at the time HMBA was injected into the animals in groups 2, 3, 4, and 5. Bidimential tumor measurements were performed with calipers, and tumor volume was determined using the formula for a rotational ellipsoid (L Â W 2 Â 0.5). Survival of all animals was followed for up to 120 days. Mice surviving to this end point were killed, and their organs were removed for the detection of HSV-1 DNA and histopathological examination.
To detect mRNA and DNA of HSV-1 in mouse tissues, an experiment of acute HSV-1 infection was performed. Tumor-bearing mice were treated the same as group 3 animals. Mice received an i.p. injection of HMBA at a dose of 500 mg/kg body weight and then 1 Â 10 7 PFU of R849. Thereafter, the HMBA injection was repeated once a day. Three days and 6 days after the injection of R849, mice were killed and tumors, trigeminal ganglia, brain, lung, liver, and kidney were removed. Parts of tumors and other tissues were snap-frozen for extraction of RNA and/or DNA. The rest was used for histopathological examination.
Histopathlogical examination
Tumors were removed, placed in 10% buffered formalin for fixation, and embedded in paraffin wax. Sections were stained with hematoxylin and eosin (H-E). For 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) staining, tumors were placed in a fixative containing 0.2% glutaraldehyde and 2% formaldehyde in PBS for 1 h, and submerged in cold PBS. Tumor tissues were then left overnight in a substrate solution containing 1 mg/ml Xgal (Sigma, Tokyo, Japan), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM magnesium chloride in PBS and washed with PBS.
Statistical analysis
Mean tumor volumes were compared using the unpaired t-test. Po0.05 indicated a significant difference among groups. In vivo data were converted to Kaplan-Meier plots, and the significance of the difference in survival rates for the various groups was calculated using the generalized Wilcoxon statistical analysis.
Results
Susceptibility of human oral squamous cell carcinoma cells and normal keratinocytes to R849 in vitro
It was reported that the differentiation-inducing activity of HMBA was optimal at a concentration of 5 mM in erythroleukemia cells. 31, 32 When mock-infected cells were treated with 5 mM HMBA for 24 h, flat cells and elongated cells appeared (Figure 1a and b) . For viral infection, cells were infected with HSV-1 at an appropriate MOI and cultured at 371C after an adsorption period of 1 h. In FI cells infected with R849 at an MOI of 2 and cultured for 24 h, a proportion of cells became rounded, and multinucleated cells with vacuoles were observed ( Figure 1c ). The cytopathic effect of R849 was more prominent with the inclusion of 5 mM HMBA in the culture medium after adsorption (Figure 1d) .
To evaluate the effect of HMBA on the replication of R849, FI cells were infected at various MOIs and cultured for 48 h. At MOIs of 0.001, 0.01, and 0.1, 7, 8 Â 10 2 , and 9 Â 10 4 PFU/ml of virus were produced, respectively, indicating the production was MOI-dependent. When R849-infected FI cells were treated with HMBA, the viral Effect of HMBA on the antitumor activity of c 1 34.5-deficient HSV-1 S Naito et al yield was increased at HMBA concentrations greater than 0.5 mM; a marked increase was observed at a low MOI (Figure 2a) . In FI cells infected withR849 at MOIs of 0.001, 0.01, and 0.1 and cultured in the presence of 1 mM HMBA for 48 h, there was an approximate 10 000-, 250-, and eight-fold increase in the viral yield, respectively, as compared with the untreated control. The effect of HMBA was also investigated in other cell lines. After infection with R849 at an MOI of 0.1, FI, SAS, and Ca9-22 cells were cultured in the presence or absence of 5 mM HMBA, and the virus yield was determined. Ca9-22 cells were found to be the most sensitive to R849 of the three cell lines, and maximal production was achieved 96 h after infection in the absence of HMBA. There was a 10-, 28-, and 38-fold increase in FI, SAS, and Ca9-22 cells, respectively, 24 h after infection (Figure 2b ). In NHEK, however, the production of R849 was not significantly increased as observed in oral SCC cell lines. When infected cells were treated with 5 mM HMBA for 24 h, the increase of the virus yield as compared with the untreated control was only a two-fold (Figure 2b ).
Effect of hexamethylene bisacetamide on the expression of herpes simplex virus type 1 immediate early genes A previous study indicated that HMBA promoted the expression of immediate early genes in the absence of the virion trans-inducing factor VP16. The expression of the immediate early genes, but not the early and late genes of HSV-1, is unaffected by inhibitors of protein synthesis. 25 Thus, when the transcripts of immediate early genes were examined by RT-PCR, 50 mg/ml of cycloheximide was added to the culture medium after an adsorption period of 1 h, irrespective of the presence of HMBA. In FI cells infected with R849 at an MOI of 2 and cultured for 2 or 5 h after infection, levels of the transcripts of ICP0, ICP4, and ICP27 were increased in the presence of 5 mM HMBA as compared with the untreated control ( Figure 3 ). When FI cells were pretreated with HMBA for 2 h and then cultured in the presence of HMBA, a marked increase in the amounts of mRNA of ICP0, ICP4, and ICP27 was observed. The expression of these genes remained at high levels, even if HMBA was withdrawn from the culture medium after adsorption.
Effect of hexamethylene bisacetamide on the viability of oral squamous cell carcinoma cells and normal keratinocytes Whether HMBA could enhance the antitumor activity of R849 was examined by trypan blue staining. When FI cells were infected at MOIs of 0.01, 0.1, and 1 and incubated for 24 h, 25, 30, and 36% of cells were trypan blue positive, respectively, whereas 48, 52, and 63% of cells were positive with the inclusion of 5 mM HMBA in the culture medium (Figure 4a ). In contrast, the proportion of dead cells was not specifically altered by treatment with HMBA in mock-infected cells.
To further examine the effect of HMBA on the antitumor activity of R849, FI, SAS, and Ca9-22 cell were infected with R849 at different MOIs and cultured in the presence or absence of 5 mM HMBA, and the cell viability was measured by MTT assay. In all cancer cell lines tested, HMBA decreased the proportion of viable cells by 96 h after infection (Figure 4b ).
In FI, SAS, and Ca9-22 cells that were infected with R849 at an MOI of 0.1 and cultured for 24 h, the cell 16, 19 , and 25%, respectively. In contrast, the decrease of the cell viability in NHEK was marginal and the cell viability was decreased by 3% in the presence of HMBA for 24 h.
Effect of R849 and hexamethylene bisacetamide on the induction of apoptosis in FI cells
The involvement of apoptosis in HMBA-induced cell death was examined. When mock-infected FI cells were treated with 5 mM HMBA for 48 h and subjected to flow cytometric analysis, a minimal proportion were in sub-G1, showing signs of apoptosis including DNA fragmentation (Figure 5a and b) . Among FI cells infected with R849 at an MOI of 2 and cultured for 48 h, 8% were in sub-G1, but this increased to 28% on the addition of 5 mM HMBA to the culture medium (Figure 5c and d) . There was no increase of the cell population in sub-G1 after treatment with HMBA in parental HSV-1(F)-infected cells (Figure 5e and f) .
The involvement of apoptosis was further examined by nuclear staining with Hochest 33342. In FI cells infected with R849 at an MOI of 2 and cultured for 48 h, 15% of the cells were apoptotic, showing fragmentation of nuclear DNA (Figure 6 ). After treatment with 5 mM HMBA for 48 h, the proportion of apoptotic cells was increased to 32% ( Figure 6 ). When FI cells were infected with HSV-1(F) and treated with HMBA for 48 h, 8% of the cells were found to be apoptotic.
Effect of R849 and hexamethylene bisacetamide on the growth of FI xenografts in nude mice The effect of R849 and HMBA on oral SCC was examined in vivo. Group 1, 2 and 3 animals received injections of R849 into subcutaneous tumors. Furthermore, groups 2 and 3 animals were given either i.t. injections or i.p. injections of HMBA, from 1 day prior to the R849 injection until 5 days after the viral injection. In untreated group 6 animals, tumors grew rapidly (Figure 7) , whereas the tumor growth in R849-treated animals (groups 1-3) was suppressed remarkably. Fifty days later, the average tumor volume in groups 1, 2, and 3 was 60, 20, and 12 mm 3 compared to 650 mm 3 for untreated control tumors. There was a significant difference between group 6 and group 1 (Po0.001), group 2 (Po0.001) or group 3 (Po0.001). No significant difference was observed between untreated controls and animals that received i.t. injections (group 4) or i.p. injections of HMBA (group 5) only. Although the injection of R849 suppressed the growth of tumors in group 1, 2, and 3 animals, tumor growth occurred in group 1 and 2 animals from 55 days after R849 injection. Effect of HMBA on the antitumor activity of c 1 34.5-deficient HSV-1 S Naito et al
To determine the long-term effects of R849 and HMBA, the survival rates of the animals were examined. All control tumor-bearing mice had died by day 60 of the experiment. Group 4 and 5 animals treated with either i.t. HMBA or i.p. HMBA only died within 90 days. Treatment with R849 prolonged the survival time of group 1, 2, and 3 animals. Notably, group 3 animals treated with R849 in combination with i.p injections of HMBA survived the entire observation period, 120 days ( Figure 8 ). The survival rates at 120 days for groups 1 and 2 were 60 and 80%, respectively. When the survival rate was compared among groups, the value in control group 6 was significantly different from that in group 1 (Po0.01), group 2 (Po0.05), or group 3 (Po0.01). The prolongation of survival time was significantly different for group 3 compared to group 1 (Po0.01), indicating that i.p. injections of HMBA had a significantly better antitumor effect than R849 only. In contrast, the difference between group 6 and group 4 or group 5 was not significant, indicating that i.t. injections or i.p. injections of HMBA alone did not prolong the survival time of the animals.
Histopathological examination of R849-treated tumors
The subcutaneous tumors in the buccal region were given 1 Â 10 7 PFU of R849 and HMBA in a similar manner to group 3 animals. Six days later, the subcutaneous tumors were excised with surrounding tissues and subjected to histopathologial examination by staining with H-E (Figure 9a) . The histological analysis of FI xenografts in nude mice demonstrated positive staining for X-gal Figure 7 Effect of R849 and hexamethylene bisacetamide (HMBA) on the growth of FI xenografts in nude mice. Tumor-bearing animals were divided into six groups; six animals each. Group 1, 2, and 3 animals were treated with an i.t. injection of 1 Â 10 7 PFU of R849 (arrow). Furthermore, group 2 and 3 animals were given an i.t. injection of 100 ml of 10 mM HMBA and i.p. injection of 500 mg/kg HMBA, respectively, six times, beginning from 1 day prior to the R849 injection. Group 4 and 5 animals were not given R849, but treated with i.t. injections of HMBA and i.p. injections of HMBA, respectively. Group 6 animals received phosphate-buffered saline instead of R849 and were used as a control. Tumor volume was measured during the experiment. Figure 8 Effect of R849 and hexamethylene bisacetamide (HMBA) on the survival of tumor-bearing mice. Tumor-bearing mice in groups 1, 2, 3, 4, 5, and 6 were treated as described in Figure 7 . KaplanMeier survival plots were constructed for tumor-bearing nude mice.
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Expression of the herpes simplex virus type 1 gene in R849-injected tumors
Whether HMBA affects the expression of viral genes was examined in vivo. Tumor-bearing mice were treated in a similar manner to groups 1 and 3, and tissues were obtained 3 and 6 days after R849 injection. Total RNAs were prepared from tumors and then subjected to RT-PCR analysis. The immediate early genes ICP0 and ICP4, early gene TK, and late gene VP16 were expressed in the tumors, and the amounts of the transcripts were increased by i.p. injections of HMBA (Figure 10 ). In the case of ICP27, the expression was only detectable 6 days after treatment with HMBA.
To determine whether HMBA could promote the spread of HSV-1 infection in the treated animals, DNAs from tumors, trigeminal ganglia, brain, lung, liver and kidney were subjected to PCR analysis. The lacZ gene and early ICP6 gene were detected in tumors and trigeminal ganglia, but not in lung, brain, liver, and kidney ( Figure 11 ). Three days after injection of R849, the amounts of the lacZ gene and early gene ICP6 in animals treated with HMBA were greater than those in animals treated with R849 only, although they were decreased 6 days later. When DNAs were prepared from group 3 animals, 120 days after viral injection and examined for the presence of ICP6 and lacZ genes by PCR, no signals were detected in these tissues, indicating that R849 did not infect tumor cells and trigeminal neurons latently (data not shown).
Discussion
Wong et al. 15 stated that a potentially important benefit of the NV1020 attenuation strategy is the retention of one intact g 1 34.5 gene copy, which may broaden its efficacy and applicability in the treatment of malignant tumors. In addition, the intact ribonucleotide reductase (RR) gene in NV1020 permits viral replication regardless of the host cell's endogenous RR levels. In the case of G207, both the genes encoding g 1 34.5 and the large subunit of viral RR are inactivated to increase safety and to prevent viral growth in nondividing cells. 12 A direct comparison between G207 and NV1020 in human tumor lines has found that the antitumor activity of NV 1020 is greater than that of G207 at lower viral concentrations. 33 In R849, the 1-kb pair deletion from HSV-1(F) was replaced with the lacZ gene. Mutations were present in both copies of the g 1 34.5 gene. Thus, it was suspected that R849 was more attenuated than NV1020, but more potent than G207 because of the presence of the RR gene. a b c Figure 9 Histopathological examination of R849-treated tumors. The tumor-bearing mice were treated with 1 Â 10 7 PFU of R849 and i.p. injections of HMBA the same as group 3 animals. Six days after the R849 injection, histological change was examined by H-E staining (a) and X-gal staining to demonstrate the expression of the lacZ gene (b, c). Effect of HMBA on the antitumor activity of c 1 34.5-deficient HSV-1 S Naito et al Lee et al. 13 reported that higher concentrations of HMBA were toxic to all the human pancreatic carcinoma cell lines they tested, and so performed experiments at a concentration of 0.5 mM. They found a modest increase in the production of G207 after 4 h of exposure to 0.5 mM HMBA for all pancreatic cancer cell lines; the increase was 1.5 to 35-fold. However, the enhancing effect of HMBA on oncolytic therapy had not been studied in vivo.
In the present study, we found that 5 mM HMBA was not cytotoxic to oral SCC cells, and all oral SCC cell lines tested were susceptible to R849 infection, showing a dosedependent increase in viral production. We also found that HMBA increased the production of R849 markedly at concentrations ranging from 0.5 to 5 mM, and a more prominent effect was observed when only a small amount of virus was inoculated. Thus, combination therapy with HMBA is considered to have an advantage over use of the oncolytic virus alone, because the inoculated virus is expected to spread to neighboring cells in solid tumors.
It was reported that HMBA enhanced the effect of in1814 if added at the early phase of HSV-1 infection. 25 Consistent with this, we found that HMBA increased the transcription of HSV-1 immediate early genes encoding ICP0, ICP4 and ICP27. It is likely that HMBA promotes the gene expression of R849 at an early phase of infection in oral SCC cells, leading to the increase in viral yield. Another finding is that pretreatment with HMBA also promoted the expression of HSV-1 immediate early genes; the effect became more remarkable with pretreatment and continuous treatment after adsorpton. In this regard, Mcfarlane et al. 25 stated that demethylation of DNA was not involved in the effect on in1814 by HMBA, but HMBA presumably affected pre-existing cellular or viral components and acted to stimulate the transcription of immediate-early genes. Thus, the effect of HMBA may be ascribed to the synthesis and/or activation of cellular proteins such as transcription factors responsible for the expression of immediate early genes of HSV-1.
Viral replication resulted in a reduction in the number of viable cells in an MOI-dependent manner. Consistent with the effect on the viral replication, HMBA treatment further decreased the proportion of viable cells. In contrast, treatment with HMBA did not alter the proportion of dead cells among mock-infected cells. Thus, HMBA itself seems to be insufficient to decrease cell viability, but rather promotes viral replication and enhances the cytopathic effect in tumor cells. Coukos et al. 10 indicated that loss of p53 function did not affect the sensitivity of epithelial ovarian cancer cells to the oncolytic effect of HSV-1 R3616 lacking the g 1 34.5 gene. Of three cell lines tested, SAS has the wild-type p53, and Ca9-22 cells have a mutation in the p53 gene. 34 Although the susceptibility of these cell lines to R849 infection was not identical, we found a similar enhancing effect of HMBA on the R849-mediated cell killing. Thus, it is unlikely that p53 status in oral SCC cells influences the effectiveness of HMBA in R849-mediated oncolytic therapy.
Although the mechanisms of cell killing by oncolytic HSV-1 mutants have not been characterized, it is known Figure 11 Existence of viral DNA in R849-injected mice. Tumor-bearing mice were treated as described in Figure 10 . Tumors, trigeminal ganglia, brain, lung, liver, and kidney were removed 3 and 6 days after the viral injection. DNAs were examined for the presence of lacZ and herpes simplex virus type 1 ICP6 genes by polymerase chain reaction.
Effect of HMBA on the antitumor activity of c 1 34.5-deficient HSV-1 S Naito et al that wild-type HSV-1 can kill cells by apoptosis or cell lysis. 35, 36 Several HSV proteins, such as viral tegumentassociated protein and US3, US5, and g 1 34.5 gene products have been implicated in the induction or prevention of apoptosis. The product of the g 1 34.5 gene prevents the premature shut-off of protein synthesis and often apoptosis by decreasing the accumulation of phosphorylated eIF-2a subunit in the infected host. 37 It was reported that both chemosensitive and chemotherapy-resistant endoepithelial ovarian cancer cell lines were equally sensitive to oncolysis by HSV-1 R3616 and underwent cell death via apoptosis or nonapoptotic mechanisms. 10 In the present study, Hoechst staining revealed that R849 infection could produce a small population of apoptotic cells, and HMBA expanded this population. However, in the situation where parental HSV-1(F) did not induce apoptosis, the enhancing effect of HMBA was not remarkable. Flow cytometric analysis also indicated that HMBA produced an apoptotic cell population in sub-G1 in cultures infected with R849, but not HSV-1(F). Hexamethylene bisacetamide promotes cell death, if the virus has the potential to induce apoptosis in the virus-cell system. This function of HMBA should contribute to cell killing in oncolytic therapy with R849.
Carew et al. 14 reported that percutaneous injections of G207 could not inhibit the growth of oral SCC xenografts in nude mice completely. Although R4009 with a stop codon in the g 1 34.5 gene prolonged the median survival of mice inoculated with D-54MG glioma cells, the survival rate 80 days after inoculation was 10%. 27 In the present study, we found that the growth of R849-injected tumors was significantly suppressed, whereas control tumors increased significantly for 9 weeks, indicating that R849 has a potent antitumor effect on human oral SCC in vivo. However, as described in other virus-tumor systems, a single injection of this g 1 34.5 gene-deficient mutant alone was also insufficient to eradicate oral SCC in nude mice, and tumor growth occurred after an interval. To overcome this shortcoming, we attempted to promote the replication of R849 in the tumors by treatment with HMBA. As the method of administration, HMBA was injected either directly into the tumor at a concentration of 10 mM or intraperitoneally at a dose of 500 mg/kg referring to the dose in our previous study. 38 Furthermore, HMBA treatment was initiated from 1 day prior to R849 injection and then continued for a subsequent 5 days, because pretreatment of cells with HMBA increased the expression of immediate early HSV-1 genes markedly in vitro. Notably, the i.p. injection of HMBA significantly enhanced the tumor-suppressive effect of R849 and, as a consequence, all tumors became undetectable, and the survival of tumor-bearing mice was prolonged. The levels of transcripts of immediate-early, early, and late genes were all equivocally increased in the presence of HMBA, and immunohistochemical analysis identified the expression of the lacZ gene product in the tumors. Thus, it was concluded that HMBA promoted the replication of R849 and increased the number of infected cells, leading to the eradication of the tumors.
Despite the enhanced oncolytic capability, neither general side effects nor neurologic disorders were observed in HMBA-treated mice. Viral DNA was detectable in trigeminal neurons during acute infections, but not long-term. No signals were found in brain, lung, liver, or kidney in the acute phase. Furthermore, normal keratinocytes was not so permissive for the replication of R849 as oral SCC cells and the effects of HMBA on the viral replication and cell viability in normal cells were marginal, suggesting that HMBA will not simply raise viral replication in both cancer cell and normal cells. These findings indicate the safety of combination therapy with R849 and HMBA.
Earlier attempts to differentiate a number of malignant cells using the differentiation-inducing activity of HMBA showed that an optimal concentration of HMBA, that is, 5 mM, could not be attained by continuous administration of HMBA in cancer patients. Egorin et al. 39 reported that doses of 24-33.6 g/m 2 /day consistently produced plasma HMBA stead-state concentrations of 1-2 mM. However, the results of the present study suggest that HMBA at a concentration of 0.5 mM was effective in promoting the replication of R849 in culture. In our previous study, when hamsters were given an i.p. injection of HMBA at a dose of 500 mg/kg, the serum concentration 1 h later was 0.17 mM. 38 Here, we indicated that i.p. injections of the same dose of HMBA into mice promoted the expression of HSV-1 genes, reduced tumor volume, and prolonged survival significantly. Furthermore, the i.t. injection of 10 mM HMBA could suppress tumor growth, although it was less effective than the i.p. injection, probably, because of the limited amounts of HMBA administered. These findings suggest that there is no need to maintain a high concentration of HMBA in tumors during oncolytic therapy. In conclusion, the differentiating agent HMBA can be used as a promoting agent for oncolytic therapy with g 1 34.5-deficient HSV-1.
